A5038520067- Pregnancy and preeclampsia studies
- Maternal and fetal healthcare
- Reproductive System and Pregnancy
- Cardiovascular Issues in Pregnancy
- Systemic Lupus Erythematosus Research
- Birth, Development, and Health
- Gynecological conditions and treatments
- Gestational Diabetes Research and Management
- Endometriosis Research and Treatment
- Health and Lifestyle Studies
- Pregnancy and Medication Impact
- Blood Coagulation and Thrombosis Mechanisms
- Infant Nutrition and Health
- Preterm Birth and Chorioamnionitis
- Infant Development and Preterm Care
- Assisted Reproductive Technology and Twin Pregnancy
- Cancer Risks and Factors
Instituto de Salud Carlos III
2020-2025
Universitat Autònoma de Barcelona
2013-2025
Hospital de Sant Pau
2019-2025
United States Nuclear Regulatory Commission
2025
To compare clinical features, laboratory data and fetal-maternal outcomes between 1000 women with obstetric APS (OAPS) 640 aPL-related complications not fulfilling Sydney criteria (non-criteria OAPS, NC-OAPS).This was a retrospective prospective multicentre study from the European Registry on Obstetric Antiphospholipid Syndrome.A total of 1650 5251 episodes, 3601 which were historical latest included. Altogether, cases (OAPS group) fulfilled classification 650 (NC-OAPS did not. Ten NC-OAPS...
ABSTRACT Objective A soluble fms‐like tyrosine kinase‐1 (sFlt‐1)‐to‐placental growth factor (PlGF) ratio cut‐off of 38 is currently considered optimal for ruling out pre‐eclampsia (PE); however, implementation this in clinical practice limited. N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) elevated PE owing to the cardiovascular effects disease. This study aimed identify predictive performance NT‐proBNP detect and placental complications within 1 week after assessment, compare it...
Abstract Introduction Increased soluble fms‐like tyrosine kinase to placental growth factor ratio (sFlt‐1/PlGF) has been demonstrated in early‐onset fetal restriction (FGR) and small for gestational age (SGA). sFlt‐1/PlGF cut‐offs have described assess preeclampsia severity; however, values present SGA different FGR severity stages remain unknown. Hence, the objective of this study was describe compare pregnancy outcomes among SGA/FGR stages. Material methods This is a prospective...
Preeclampsia is caused by placental impairment with increased expression of sFlt-1 (soluble fms-like tyrosine kinase 1) and decreased PlGF (placental growth factor); it has been associated cardiovascular morbidity mortality later in life, but the underlying mechanism remains unknown. The aim this study was to determine whether levels during preeclampsia are long-term risk. We prospectively recruited 43 women previous 21 controls uncomplicated pregnancies. Cardiovascular risk assessment ≈12...
N-terminal pro-brain natriuretic peptide (NT-proBNP) and uric acid are elevated in pregnancies with preeclampsia (PE). Short-term prediction of PE using angiogenic factors has many false-positive results. Our objective was to validate a machine-learning model (MLM) predict patients clinical suspicion, evaluate if the performed better than sFlt-1/PlGF ratio alone. A multicentric cohort study suspected between 24+0 36+6 weeks used. The MLM included six predictors: gestational age, chronic...
Introduction: Preterm birth is the leading cause of perinatal mortality worldwide, with prevalence rates showing little reduction. Although have decreased, morbidity remain concerningly high. In recent years, there has been a surge in studies examining etiology, risk factors, and management preterm birth. The use vaginal probiotics pregnant women at garnered attention as potential approach for improving outcomes modulating microbiota. However, efficacy this intervention remains unclear....
Background: Vasa previa consists in the presence of extraplacental fetal vessels overlying cervix. This condition is commonly associated with fatal outcome if prenatally undiagnosed. Two types vasa have been classically described, well-established risk factors. However, a rare third type has also reported. Case: We present case 3 diagnosed second trimester, two The placenta was unilobed, not previa, and cord insertion marginal. Placental examination after delivery confirmed prenatal...
Cardiovascular diseases (CVD) are cause of increased morbidity and mortality in spite advances for diagnosis treatment. Changes during pregnancy affect importantly the maternal CV system. Pregnant women that develop preeclampsia (PE) have higher risk (up to 4 times) clinical CVD short- long-term. Predominance an anti-angiogenic environment is known as main PE, but its relationship with complications still under research. We hypothesize angiogenic factors associated cardiac...